{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T15:26:30Z","timestamp":1778858790070,"version":"3.51.4"},"reference-count":23,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Journal of Otolaryngology"],"published-print":{"date-parts":[[2024,1]]},"DOI":"10.1016\/j.amjoto.2023.104065","type":"journal-article","created":{"date-parts":[[2023,10,11]],"date-time":"2023-10-11T21:46:05Z","timestamp":1697060765000},"page":"104065","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Real-world data of immunotherapy from China in recurrent or metastatic head and neck squamous cell carcinoma"],"prefix":"10.1016","volume":"45","author":[{"given":"Ximei","family":"Zhang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peiguo","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yanlan","family":"Chai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xuan","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ping","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xudong","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.amjoto.2023.104065_bb0005","first-page":"7","article-title":"Cancer statistics","volume":"70","author":"Siegel","year":"2020","journal-title":"Clin CA Cancer J"},{"issue":"9625","key":"10.1016\/j.amjoto.2023.104065_bb0010","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1016\/S0140-6736(08)60728-X","article-title":"Head and neck cancer","volume":"371","author":"Argiris","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.amjoto.2023.104065_bb0015","author":"World Health Organization"},{"issue":"2","key":"10.1016\/j.amjoto.2023.104065_bb0020","first-page":"115","article-title":"Cancer statistics in China, 2015","volume":"66","author":"Chen","year":"2016","journal-title":"CA Cancer J Clin"},{"issue":"1","key":"10.1016\/j.amjoto.2023.104065_bb0025","first-page":"29","article-title":"Systemic therapy in the curative treatment of head and neck squamous cell cancer: a systematic review","volume":"46","author":"Winquist","year":"2017","journal-title":"J Otolaryngology"},{"issue":"5","key":"10.1016\/j.amjoto.2023.104065_bb0030","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1016\/j.ijrobp.2012.05.008","article-title":"Long-term follow-up of the RTOG 9501\/intergroup Phase III trial: postoperative concurrent radiation therapy and chemotherapy in high-risk squamous cell carcinoma of the head and neck","volume":"84","author":"Cooper","year":"2012","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"19","key":"10.1016\/j.amjoto.2023.104065_bb0035","first-page":"1945","article-title":"Postoperative irradiation with or without concomitant chemotherapy for locally advanced head and neck cancer. N.Engl","volume":"350","author":"Bernier","year":"2004","journal-title":"J.Med."},{"issue":"1","key":"10.1016\/j.amjoto.2023.104065_bb0040","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.radonc.2009.04.014","article-title":"Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): an update on 93 randomised trials and 17,346 patients","volume":"92","author":"Pignon","year":"2009","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.amjoto.2023.104065_bb0045","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.oraloncology.2018.07.005","article-title":"Clinical outcomes with therapies for previously treated recurrent\/metastatic head-and-neck squamous cell carcinoma (R\/M HNSCC): a systematic literature review","volume":"84","author":"Lala","year":"2018","journal-title":"Oral Oncol"},{"issue":"10","key":"10.1016\/j.amjoto.2023.104065_bb0050","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1586\/era.09.113","article-title":"Cetuximab in metastatic or recurrent head and neck cancer: the EXTREME trial","volume":"9","author":"Rivera","year":"2009","journal-title":"Expert Rev Anticancer Ther"},{"issue":"10167","key":"10.1016\/j.amjoto.2023.104065_bb0055","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/S0140-6736(18)31999-8","article-title":"Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, Phase III study","volume":"393","author":"Cohen","year":"2019","journal-title":"Lancet"},{"issue":"19","key":"10.1016\/j.amjoto.2023.104065_bb0060","doi-asserted-by":"crossref","first-page":"1856","DOI":"10.1056\/NEJMoa1602252","article-title":"Nivolumab for recurrent squamous-cell carcinoma of the head and neck","volume":"375","author":"Ferris","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.amjoto.2023.104065_bb0065","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1016\/S0140-6736(19)32591-7","article-title":"Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study","volume":"23; 394(10212)","author":"Burtness","year":"2019","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.amjoto.2023.104065_bb0070","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1055\/s-0041-1729443","article-title":"Real-world experience of immunotherapy from India in recurrent squamous cell carcinoma of head and neck cancer","volume":"10","author":"Abbas","year":"2021","journal-title":"South Asian J Cancer"},{"issue":"1","key":"10.1016\/j.amjoto.2023.104065_bb0075","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1186\/s12885-020-07214-4","article-title":"Clinical outcomes of immune checkpoint inhibitors for patients with recurrent or metastatic head and neck cancer: real-world data in Korea","volume":"20","author":"Kim","year":"2020","journal-title":"BMC Cancer"},{"issue":"11","key":"10.1016\/j.amjoto.2023.104065_bb0080","doi-asserted-by":"crossref","first-page":"3427","DOI":"10.3390\/cancers12113427","article-title":"Real-world, long term outcomes of nivolumab therapy for recurrent or metastatic squamous cell carcinoma of the head and neck and impact of the magnitude of best overall response: a retrospective multicenter study of 88 patients","volume":"12","author":"Matsuki","year":"2020","journal-title":"Cancers (Basel)"},{"issue":"1","key":"10.1016\/j.amjoto.2023.104065_bb0085","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1200\/JCO.20.00290","article-title":"Randomized phase II trial of nivolumab with stereotactic body radiotherapy versus nivolumab alone in metastatic head and neck squamous cell carcinoma","volume":"39","author":"McBride","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.amjoto.2023.104065_bb0090","doi-asserted-by":"crossref","first-page":"e1508","DOI":"10.1002\/onco.13810","article-title":"Phase I trial of cemiplimab, radiotherapy, cyclophosphamide, and granulocyte macrophage colony-stimulating factor in patients with recurrent or metastatic head and neck squamous cell carcinoma","volume":"26","author":"Babiker","year":"2021","journal-title":"Oncologist"},{"key":"10.1016\/j.amjoto.2023.104065_bb0095","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.ejca.2019.03.022","article-title":"Clinical outcomes and prognostic factors in recurrent and\/or metastatic head and neck cancer patients treated with chemotherapy plus cetuximab as first-line therapy in a real-world setting","volume":"115","author":"Depenni","year":"2019","journal-title":"Eur J Cancer"},{"issue":"10","key":"10.1016\/j.amjoto.2023.104065_bb0100","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0223154","article-title":"Early mortality after diagnosis of cancer of the head and neck-A population-based nationwide study","volume":"14","author":"Talani","year":"2019","journal-title":"PloS One"},{"key":"10.1016\/j.amjoto.2023.104065_bb0105","doi-asserted-by":"crossref","unstructured":"Antonia SJ, Borghaei H, Ramalingam SS, et al (2019) Four-year survival with nivolumab in patients with previously treated advanced non-small-cell lung cancer: a pooled analysis. Lancet Oncol 2019; 20(10):1395\u20131408.","DOI":"10.1016\/S1470-2045(19)30407-3"},{"issue":"6","key":"10.1016\/j.amjoto.2023.104065_bb0110","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1111\/cas.14015","article-title":"Long-term follow up of nivolumab in previously untreated Japanese patients with advanced or recurrent malignant melanoma","volume":"110","author":"Yamazaki","year":"2019","journal-title":"Cancer Sci"},{"key":"10.1016\/j.amjoto.2023.104065_bb0115","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1016\/j.annonc.2022.04.450","article-title":"Deciphering radiological stable disease to immune checkpoint inhibitors","volume":"33","author":"Luo","year":"2022","journal-title":"Ann Oncol"}],"container-title":["American Journal of Otolaryngology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S019607092300279X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S019607092300279X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T05:13:44Z","timestamp":1759295624000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S019607092300279X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1]]},"references-count":23,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,1]]}},"alternative-id":["S019607092300279X"],"URL":"https:\/\/doi.org\/10.1016\/j.amjoto.2023.104065","relation":{},"ISSN":["0196-0709"],"issn-type":[{"value":"0196-0709","type":"print"}],"subject":[],"published":{"date-parts":[[2024,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Real-world data of immunotherapy from China in recurrent or metastatic head and neck squamous cell carcinoma","name":"articletitle","label":"Article Title"},{"value":"American Journal of Otolaryngology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.amjoto.2023.104065","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"104065"}}